The FDA agreed to review the company's treatment for a swelling disease.
Why This Biotech, Up 12% Since Its Breakout, Yo-Yoed On A Key FDA Development
Licensing
Pharvaris (PHVS) stock jumped early Monday, but closed in the red, after the Food and Drug Administration agreed to review the biotech company's experimental treatment for a serious swelling disease. The drug, deucrictibant immediate-release, would treat the sudden swelling attacks associated with hereditary angioedema, or HAE. The FDA will make a decision on whether to approve deucrictibant by April 23.…
Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease.
The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a…
Four months after Theravance Biopharma shut down its R&D unit, laid | Four months after Theravance Biopharma shut down its R&D…
The bank initiated the clinical-stage biotechnology firm at a buy rating.
The investment bank upgraded the pharma stock to overweight from equal weight.
Maryland drug board to cap price of Ozempic, TrumpRx partners with Cuban, GoodRx, and more biotech news
